Disorders of Dental Hard Tissues Induced by Radioiodine-131 (I-131) Therapy Used in Differentiated Thyroid Cancer: An In Vitro Study

被引:3
|
作者
Mester, Alexandru [1 ]
Piciu, Andra [2 ]
Piciu, Doina [3 ]
Petean, Ioan [4 ]
Lucaciu, Patricia Ondine [1 ]
Apostu, Dragos [5 ]
Moisescu-Goia, Cristina [3 ]
Voina-Tonea, Andrada [6 ]
Moldovan, Marioara [7 ]
机构
[1] Univ Med & Pharm Iuliu Hatieganu, Dept Oral Hlth, Cluj Napoca 400012, Romania
[2] Univ Med & Pharm Iuliu Hatieganu, Dept Med Oncol, Cluj Napoca 400012, Romania
[3] Univ Med & Pharm Iuliu Hatieganu, Oncol Inst Ion Chiricuta, Dept Endocrine Tumors & Nucl Med, Cluj Napoca 400012, Romania
[4] Univ Babes Bolyai, Fac Chem & Chem Engn, Cluj Napoca 400294, Romania
[5] Univ Med & Pharm Iuliu Hatieganu, Dept Orthoped, Cluj Napoca 400012, Romania
[6] Univ Med & Pharm Iuliu Hatieganu, Dept Dent Mat, Cluj Napoca 400012, Romania
[7] Univ Babes Bolyai, Inst Chem Raluca Ripan, Dept Polymer Composites, Cluj Napoca 400294, Romania
关键词
oral disease; differentiated thyroid cancer; radioiodine therapy; dental hard tissue; RADIOACTIVE IODINE; ENAMEL; TEETH; MICROHARDNESS;
D O I
10.3390/biomedicines8110475
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
This study aimed to evaluate, in vitro, the effects of I-131 on enamel and dentin in healthy human incisive permanent maxillary teeth. Our in vitro model analogue with the in vivo conditions of differentiated thyroid carcinoma patients treated with I-131, consisted in a solution of I-131 dissolved in artificial saliva. A total of 48 teeth were divided into eight groups (n = 6): control, irradiation groups at 3, 6, 12, 24, 36, 48, and 192 h, respectively. At the end of radiation exposure, radioiodine activity of specimens was assessed. Fine microstructure, nanostructure, surface roughness, and hidroxyapatite (HAP) crystallite diameter were investigated by atomic force microscopy (AFM) to both enamel and dentin structures. There is a constant increase of radioactivity in dental structures at 3, 6, 12, 24 h, due to progressive retention and I-131 migration, with a maximum at 36 h. Enamel showed notable alterations, which was correlated with the increase of the treatment time. A relevant visible distance between the HAP prisms was observed after 24 h. The surface suffered a loss in its compact structure. I-131 acts in the same way on HAP crystallites in dentin as in those in enamel. It was noticed that their morpho-dimensional changes occurred only after 12 h of treatment. Radioiodine-131 determines degradation of enamel and dentin by starting from the alteration of the crystalline network of HAP prisms, transforming them from compact materials into an agglomeration of rocky submicron structures.
引用
收藏
页码:1 / 10
页数:10
相关论文
共 50 条
  • [21] Effects of Dosimetrically Guided I-131 Therapy on Hematopoiesis in Patients With Differentiated Thyroid Cancer
    Bikas, Athanasios
    Schneider, Mark
    Desale, Sameer
    Atkins, Frank
    Mete, Mihriye
    Burman, Kenneth D.
    Wartofsky, Leonard
    Van Nostrand, Douglas
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2016, 101 (04): : 1762 - 1769
  • [22] THYROID CANCER FOLLOWING I-131 THERAPY OF HYPERTHYROIDISM
    LIMA, JB
    CATZ, B
    PERZIK, SL
    JOURNAL OF NUCLEAR MEDICINE, 1970, 11 (01) : 46 - &
  • [23] The Benefits and Risks of I-131 Therapy in Patients with Well-Differentiated Thyroid Cancer
    Van Nostrand, Douglas
    THYROID, 2009, 19 (12) : 1381 - 1391
  • [24] The efficiency of planning of therapeutic 131I activities in the radioiodine therapy of differentiated thyroid cancer
    Sinyuta, B
    Dzhuzha, D
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE, 2001, 28 (08): : 1004 - 1004
  • [25] THYROID CANCER DETECTED AFTER I-131 THERAPY
    WAIGHT, PJ
    JOURNAL OF NUCLEAR MEDICINE, 1970, 11 (07) : 471 - &
  • [26] Redifferentiation of radioiodine-refractory differentiated thyroid cancer to warrant I-131 therapy using lenvatinib: results of the RESET trial
    Dotinga, M.
    Kapiteijn, E.
    van Velden, F. H. P.
    Stam, M. K.
    Dibbets-Schneider, P.
    Pool, M.
    Smit, F.
    de Geus-Oei, L. F.
    Vriens, D.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2024, 51 : S202 - S202
  • [27] Managing radioiodine refractory thyroid cancer: the role of dosimetry and redifferentiation on subsequent I-131 therapy
    Dotinga, Maaike
    Vriens, Dennis
    van Velden, Floris
    Heijmen, Linda
    Nagarajah, James
    Hicks, Rodney
    Kapiteijn, Ellen
    de Geus-Oei, Lioe-Fee
    QUARTERLY JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2020, 64 (03): : 250 - 264
  • [28] Outcome of radioiodine-131 therapy in hyperfunctioning thyroid nodules: a 20 years' retrospective study
    Ceccarelli, C
    Bencivelli, W
    Vitti, P
    Grasso, L
    Pinchera, A
    CLINICAL ENDOCRINOLOGY, 2005, 62 (03) : 331 - 335
  • [29] I-131 therapy in differentiated thyroid carcinoma patients with high thyroglobulin levels despite negative diagnostic I-131 scans
    Akgun, A.
    Yazici, B.
    Erdim, O.
    Ozcan, Z.
    Ozkilic, H.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2006, 33 : S330 - S330
  • [30] The value of I-131 SPECT in the detection of recurrent differentiated thyroid cancer
    Geerlings, Jackelien A. C.
    van Zuijlen, Anke
    Lohmann, Ellen M.
    Smit, Jan W. A.
    Stokkel, Marcel P. M.
    NUCLEAR MEDICINE COMMUNICATIONS, 2010, 31 (05) : 417 - 422